ESMO 2026 at a glance
ESMO 2026 will spotlight emerging oncology trends as antibody-drug conjugates, earlier-stage treatment strategies, precision oncology, next-generation immunotherapies and AI-enabled clinical tools compete to demonstrate meaningful clinical differentiation and patient benefit.
📅 Build your schedule around the topics that matter most.
📥 Download the ESMO 2026_Preview_by_LucidQuest
ESMO 2026: Key Oncology Trends and Clinical Developments
The ESMO Congress 2026 will bring attention to a central question for oncology drug development: which innovations can demonstrate sufficient clinical value to reshape established treatment pathways?
LucidQuest is watching four major areas of clinical and competitive differentiation.
Antibody-Drug Conjugates: HER2, CLDN18.2 and TROP2 Differentiation
HER2-, CLDN18.2- and TROP2-directed antibody-drug conjugates (ADCs) will face increasing scrutiny over efficacy, survival outcomes, safety and patient selection.
As ADC development expands across tumor types, competitive differentiation will depend on demonstrating meaningful clinical advantages rather than target selection alone.
Earlier-Stage Cancer Treatment: Perioperative and Adjuvant Strategies
Perioperative and adjuvant treatment combinations will test whether additional clinical benefit justifies increased toxicity, treatment burden and cost.
These findings may influence treatment intensification strategies and the positioning of emerging therapies in earlier-stage disease.
Non-Small Cell Lung Cancer: KRAS G12C, EGFR/MET and HER3 Treatment Sequencing
In non-small cell lung cancer (NSCLC), KRAS G12C inhibitors, EGFR/MET combinations and HER3-directed ADCs will compete on efficacy, resistance management and tolerability.
The results will be relevant to treatment sequencing and competitive positioning within increasingly complex NSCLC treatment pathways.
Precision Oncology: Biomarker-Selected and Organ-Preserving Treatment
Studies involving mismatch repair-deficient (dMMR) and microsatellite instability-high (MSI-H) tumors may support organ-preserving and chemotherapy-sparing treatment approaches.
Their clinical relevance will depend on the strength of the evidence supporting patient selection, treatment outcomes and practical adoption.
ESMO 2026: Emerging Oncology Therapies and Competitive Developments
Beyond broader treatment trends, several clinical programs and company strategies warrant attention for their potential competitive implications.
Emerging ADC Clinical Trials in Gastroesophageal and Gynecologic Cancers
Sonesitatug vedotin, arcotatug tavatecan and sacituzumab tirumotecan will generate evidence across gastroesophageal and gynecologic cancers.
Their results may help clarify how emerging ADCs differentiate across targets, tumor types and treatment settings.
KRAS G12C Inhibitors: Divarasib and the Krascendo 1 Trial
Krascendo 1 will directly compare divarasib against established KRAS G12C inhibitors, potentially clarifying within-class differentiation.
Head-to-head evidence could become particularly important as competing targeted therapies seek stronger positioning within NSCLC treatment pathways.
Next-Generation Cancer Immunotherapy: Tarlatamab and Ivonescimab
Tarlatamab and ivonescimab will test alternative immune mechanisms in small cell lung cancer (SCLC) and biliary tract cancer.
These programs highlight continued efforts to expand immunotherapy options beyond established treatment approaches.
Oncology Competitive Landscape: Pfizer, Novartis and Gilead Sciences
Pfizer’s lorlatinib, Novartis’ CDK4/6 strategy and Gilead Sciences / Kite Pharma’s ADC programmes highlight competing approaches to long-term clinical benefit and treatment positioning.
For biopharma companies, the strategic question is how differentiated efficacy, durability and tolerability translate into sustainable competitive advantages.
Artificial Intelligence and Machine Learning at ESMO 2026
AI and machine learning will feature in discussions about clinical decision support, digital oncology and the practical integration of new technologies into cancer care.
AI in Oncology: Clinical Decision Support and Multidisciplinary Care
Colorectal cancer and cholangiocarcinoma studies will assess AI-assisted multidisciplinary decisions and clinical workflow integration.
The central question is whether AI-enabled decision support can demonstrate clinical utility beyond technical performance.
Digital Oncology: AI Pathology, Toxicity Management and Recurrence Prediction
ALLIANCE, HOPE and AI-driven pathology studies will examine clinical utility in toxicity management, supportive care and recurrence-risk assessment.
These developments may help clarify the evidence needed to integrate digital oncology tools into routine clinical practice.
What to Watch Next in Oncology After ESMO 2026
ADC clinical differentiation:** Whether Phase III results establish meaningful differences in efficacy, survival and safety across targets and tumor types.
Treatment intensification and sequencing:** Whether earlier-stage combinations and resistance-directed strategies deliver sufficient benefit to change established treatment pathways.
AI in cancer care:** Whether AI-enabled tools demonstrate measurable patient benefit beyond technical validation.
Key Takeaway: Clinical Differentiation Will Shape Oncology Competition
ESMO 2026 will provide an opportunity to assess whether emerging oncology innovations can move beyond promising mechanisms and preliminary evidence to demonstrate meaningful clinical value.
Across ADCs, precision oncology, treatment intensification and next-generation immunotherapies, competitive positioning will depend on efficacy, durability, safety, patient selection and practical adoption.
For AI-enabled oncology tools, measurable clinical benefit and integration into care pathways will be equally important.
For biopharma companies, the overarching strategic question is which innovations can establish a differentiated and sustainable role in increasingly competitive treatment landscapes.
Download the LucidQuest’s ESMO 2026 Preview Report
Download LucidQuest’s ESMO 2026 preview report for a closer look at the clinical developments, emerging competitors and strategic questions shaping oncology.
📅 Build your schedule around the sessions that matter most.
📥 Download the ESMO 2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
